/wp-content/uploads/candel_logo.svg00cchan@candeltx.com/wp-content/uploads/candel_logo.svgcchan@candeltx.com2021-07-26 18:24:192025-06-16 07:43:14Candel Therapeutics Announces Pricing of Initial Public Offering
/wp-content/uploads/candel_logo.svg00cchan@candeltx.com/wp-content/uploads/candel_logo.svgcchan@candeltx.com2021-07-15 05:00:192025-06-16 07:45:10Candel Therapeutics Appoints Diem Nguyen, Ph.D., M.B.A., to its Board of Directors
/wp-content/uploads/candel_logo.svg00cchan@candeltx.com/wp-content/uploads/candel_logo.svgcchan@candeltx.com2021-05-11 05:00:172025-06-16 07:51:43Candel Therapeutics Names Carrie S. Cox as Chairman of its Board of Directors
/wp-content/uploads/candel_logo.svg00cchan@candeltx.com/wp-content/uploads/candel_logo.svgcchan@candeltx.com2021-04-29 05:00:212025-06-16 07:48:55Candel Therapeutics’ CAN-3110 Clinical Data Selected for Oral Presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
/wp-content/uploads/candel_logo.svg00cchan@candeltx.com/wp-content/uploads/candel_logo.svgcchan@candeltx.com2021-04-22 05:14:122025-06-16 07:50:44Candel Therapeutics Completes Enrollment in Phase 1 Clinical Trial of CAN-2409 in Combination with Opdivo® (nivolumab) for the Treatment of High-Grade Gliomas
/wp-content/uploads/candel_logo.svg00cchan@candeltx.com/wp-content/uploads/candel_logo.svgcchan@candeltx.com2021-04-09 05:02:342025-06-16 07:47:20Candel Therapeutics Appoints Chris Matheny, PharmD, Ph.D., as Vice President, Development Leader
/wp-content/uploads/candel_logo.svg00Vince Rose/wp-content/uploads/candel_logo.svgVince Rose2020-12-08 08:00:532025-06-16 07:46:24Candel Therapeutics Appoints Pharma Veteran and Immunologist Paul-Peter Tak, M.D., Ph.D., as Chief Executive Officer; Expands Leadership Team With Chief Financial Officer, Chief Business Officer and Chief Regulatory Officer Appointments
/wp-content/uploads/candel_logo.svg00Vince Rose/wp-content/uploads/candel_logo.svgVince Rose2020-05-30 08:00:392025-06-16 07:41:15Candel Therapeutics Announces Presentation of Clinical Data for GMCI in NSCLC at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting
/wp-content/uploads/candel_logo.svg00Vince Rose/wp-content/uploads/candel_logo.svgVince Rose2020-01-08 08:00:542025-08-13 13:09:24Candel Therapeutics acquires next-generation herpes drug development platform and manufacturing expertise